HYTRIN SUMMARY
HYTRIN®
(terazosin hydrochloride)
HYTRIN (terazosin hydrochloride) is an alpha-1-selective adrenoceptor blocking agent.
HYTRIN (terazosin hydrochloride) is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with HYTRIN. The long-term effects of HYTRIN on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined.
HYTRIN is also indicated for the treatment of hypertension. It can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.
|
NEWS HIGHLIGHTS
Published Studies Related to Hytrin (Terazosin)
Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial. [2009.07]
OBJECTIVES: To investigate the therapeutic efficacy and safety of Amlodipine alone or in combination with terazosin for the presence of lower urinary tract symptoms (LUTS) and hypertension. LUTS and hypertension often coexist in elderly men... CONCLUSIONS: The results of this 4-week, double-blind, randomized trial have demonstrated that in Chinese male hypertensive patients with LUTS, low-dose Amlodipine plus terazosin therapy appears to be a safe and effective combination therapy to control both conditions, especially for those with predominant overactive bladder symptoms.
[Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention] [2009.05]
OBJECTIVE: This prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual (PVR) in patients with lower urinary tract symptoms (LUTS) and concomitant hypertension... CONCLUSION: Amlodipine alone or combined with terazosin can improve the PVR of the LUTS patient effectively, but had no significant difference compared with terazosin.
Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial. [2008.04]
PURPOSE: We determined the clinical efficacy and safety of terazosin in the treatment of patients with female lower urinary tract symptoms... CONCLUSIONS: Terazosin proved to be more effective and safe than placebo in patients with female lower urinary tract symptoms.
Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. [2007.03.05]
BACKGROUND: The primary objectives of the treatment for the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50. In this study, we evaluated the efficacy and safety of the combined therapy with terazosin (apha1-adrenergic receptor antagonist) and tolterodine (anticholinergic agent) for LUTS associated with BPH... CONCLUSIONS: Patients with LUTS associated BPH appear the improved IPSS after combined therapy with terazosin and tolterodine. This study, although short term and limited numbers of patients, provides evidence that the combined therapy with terazosin plus tolterodine is a good approach for meeting the objectives of rapid, sustained, and safe improvements in the LUTS associated with BPH. And the profile of patients in this study might be used as the indication of such combined therapy for LUTS associated with BPH without urodynamic evaluation.
More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study. [2006]
The objective of this study was to evaluate whether extracorporeal magnetic innervation (ExMI) combined with alpha-blocker therapy is more effective than alpha-blocker monotherapy for patients with non-inflammatory chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS), category IIIB.The early results suggest that ExMI combined with alpha-blocker therapy has better effect than alpha-blocker monotherapy for the treatment of CP/CPPS.
Clinical Trials Related to Hytrin (Terazosin)
Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension [Completed]
The aim of this study was to investigate the efficacy and safety of low dose amlodipine
alone, or combined with low dose terazosin in male patients with both lower urinary tract
symptoms and hypertension.
Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up [Terminated]
The purpose of the study is to compare two alpha blockers, terazosin and doxazosin GITS, in
achieving a successful TWOC after AUR due to BPH, among Chinese males in Hong Kong, and in
delaying or avoiding a TURP.
Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin [Recruiting]
The study consists of measurement of antidepressant-induced excessive sweating and its
treatment with an experimental medication, terazosin (approved for hypertension), that will
be added to the antidepressant. This study is for people who take an antidressant due to a
depressive disorder. This is an open-label study (no placebo group) that will last 5 weeks,
with one week of baseline measurement and four weeks of treatment with the study medication.
The study is based on the hypothesis that terazosin will be effective in reducing the
severity of excessive sweating caused by antidepressant treatment, and will have minimal
side-effects.
Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating [Recruiting]
This study is based on the hypothesis that terazosin, a blocker of alpha-1 receptors, will
be effective in reducing excessive sweating caused by antidepressant treatment, and will
have minimal adverse effects.
Alpha-Blocker Plus Diuretic Combination Therapy as Second-Line Treatment for Nocturia in Men [Completed]
The aim of the present study was to determine whether the combined administration of a
diuretic agent, hydrochlorothiazide, at night would improve the frequency of nocturia
unresponsive to alpha-blocker monotherapy in men with LUTS.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Hytrin has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| | Hytrin review by 66 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | high blood presure |
| Dosage & duration: | | 2mg taken once daily for the period of 4 years |
| Other conditions: | | allergies |
| Other drugs taken: | | premerin/allegra | | |
Reported Results |
| Benefits: | | Tried many different drugs all either failed to reduce my blood presure or had side effects which I did not want to live with. Hytrin has brought my blood pressure under control with absolutely no side effects |
| Side effects: | | none at all |
| Comments: | | I take one tablet of the generic for Hytrin which is Terizosin each night and bed time and am monitored for my blood pressure control by my physician at six month intervals |
|
|
|
Page last updated: 2009-10-20
|
